Indications
Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
Composition
- Active substance
- buprenorphine hydrochloride
- International name (INN)
- buprenorphine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Sixmo
- Active substance
- buprenorphine hydrochloride
- ATC code
- N07BC01
- Group
- Nervous system
- Therapeutic area
- Opioid-Related Disorders
- Marketing authorisation holder
- L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.